RVTY vs A vs ILMN Stock Comparison

Revvity, Agilent Technologies and Illumina Prices as of Nov 2, 2026 Peers: Industry group
1 more company in this comparison (RGEN) Create a free account to keep reading and compare up to 10 companies.
RVTY Revvity, Inc.
$151.70 +0.1% 1M +62.1% 1Y
Market cap
$17.66B
P/E
74.3x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare
A Agilent Technologies, Inc.
$172.02 +2.6% 1M +17.5% 1Y
Market cap
$49.95B
P/E
34.7x
Revenue (TTM)
$7.37B
Div. yield
0.01%
Life Sciences Tools Healthcare
7 wins
ILMN Illumina, Inc.
$226.58 -17.0% 1M +83.4% 1Y
Market cap
$34.25B
P/E
38.3x
Revenue (TTM)
$4.54B
Div. yield
–
Life Sciences Tools Healthcare
5 wins

Head to Head

12 decided of 12

Agilent Technologies leads on 7 of the 12 questions below (Agilent Technologies 7, Illumina 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionRVTYAILMNLeader
Larger companyMarket capitalisation $17.66B $49.95B $34.25B A
Cheaper on earningsLower P/E, profitable companies only 74.3x 34.7x 38.3x A
Cheaper on forward earningsLower price / next fiscal year consensus EPS 32.1x 26.8x 47.7x A
Faster revenue growthRevenue growth, trailing twelve months +4.1% +8.6% +5.8% A
More profitableNet margin, trailing twelve months 8.2% 19.5% 19.7% ILMN
Better return on capitalReturn on invested capital 3.1% 13.1% 16.6% ILMN
Less leveragedLower net debt / EBITDA 2.8x 1.1x 0.4x ILMN
Higher dividend yieldTrailing dividend yield 0.00% 0.01% 0.00% A
Better 1-year returnPrice return, last 12 months +62.1% +17.5% +83.4% ILMN
Better 5-year returnAnnualised price return, 5 years -2.7%/yr +1.7%/yr -11.1%/yr A
Less volatileAnnualised volatility, 1 year 40.1% 32.6% 49.9% A
Higher overall scoreMean of the five percentile scores vs peers 58/100 62/100 75/100 ILMN

Percentile Scorecard

RVTYAILMN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisRVTYAILMN
Valuation 71 #67 of 227 57 #98 of 227 59 #94 of 227
Growth 27 #160 of 220 36 #141 of 220 73 #60 of 220
Profitability 80 #43 of 209 91 #19 of 209 99 #4 of 209
Financial Health 47 #127 of 240 56 #107 of 240 60 #96 of 240
Shareholder Returns 64 #50 of 138 68 #45 of 138 82 #26 of 138
Overall 58 62 75
  • RVTY ranked among 247 companies in Medical Devices and Diagnostics
  • A ranked among 247 companies in Medical Devices and Diagnostics
  • ILMN ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodRVTYAILMNSPY
1 month +0.1%+2.6%-17.0% -2.3%
3 months +31.7%+23.0%+14.3% -0.7%
6 months +75.4%+53.3%+62.6% +4.8%
Year to date +56.8%+26.4%+72.8% +10.3%
1 year +62.1%+17.5%+83.4% +10.3%
3 years +72.1%+57.8%+99.2% +73.0%
3 years, per year +19.8%+16.4%+25.8% +20.1%
5 years -12.9%+8.7%-44.5% +61.9%
5 years, per year -2.7%+1.7%-11.1% +10.1%
10 years +203.3%+297.6%+71.7% +258.6%
10 years, per year +11.7%+14.8%+5.6% +13.6%

Risk

MeasureRVTYAILMNSPY
Volatility, 1Y 40.1%32.6%49.9% 12.8%
Downside volatility, 1Y 36.6%27.9%49.1% 12.8%
Beta vs S&P 500, 1Y 1.250.911.06 1.00
Return / volatility, 1Y 1.550.541.67 0.80
Max drawdown, 5Y -59.2%-39.6%-82.9% -25.4%
From 52-week high -8.5%-5.2%-22.9% -3.5%
52-week high $165.78$181.54$293.69 $779.14
52-week low $82.26$110.24$114.44 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleRVTYAILMN
P/E now vs peer median 71.3xmedian 28.4x 33.7xmedian 28.4x 38.2xmedian 28.4x
P/S now vs peer median 5.8xmedian 3.0x 6.6xmedian 3.0x 7.5xmedian 3.0x
EV/EBITDA now vs peer median 24.6xmedian 18.0x 26.5xmedian 18.0x 28.0xmedian 18.0x
P/FCF now vs peer median 29.8xmedian 25.0x 38.3xmedian 25.0x 32.4xmedian 25.0x
P/B now vs peer median 2.3xmedian 2.3x 6.6xmedian 2.3x 10.9xmedian 2.3x
PEG now vs peer median -2.29median 0.93 3.43median 0.93 0.93median 0.93

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsRVTYAILMN
Revenue $2.91B $7.37B $4.54B
Gross profit $1.60B $3.97B $3.08B
Operating income $358.85M $1.64B $960.00M
Net income $237.55M $1.44B $895.00M
Free cash flow $568.85M $1.27B $1.06B
R&D $215.83M $485.00M $975.00M
EPS (diluted) $2.13 $5.09 $5.85
Cash & equivalents $1.02B $1.76B $1.29B
Total debt $3.21B $3.95B $1.79B
Shares (diluted) 111.63M 283.00M 153.00M
Enterprise value $13.93B $42.84B $28.96B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricRVTYAILMN
P/E 71.3x 33.7x 38.2x
P/FCF 29.8x 38.3x 32.4x
P/Operating cash flow 26.5x 30.1x 27.8x
P/S 5.8x 6.6x 7.5x
P/B 2.3x 6.6x 10.9x
P/Tangible book 3.4x 7.5x 12.4x
EV/EBITDA 24.6x 26.5x 28.0x
EV/EBIT 53.3x 30.9x 36.1x
EV/Revenue 6.6x 6.9x 7.6x
EV/FCF 33.6x 40.0x 32.8x
EV/Operating cash flow 29.9x 31.5x 28.2x
PEG (3Y EPS CAGR) -2.29 3.43 0.93

Growth

14 metrics
MetricRVTYAILMN
Revenue growth (1Y) 4.1% 8.6% 5.8%
Revenue CAGR (3Y) 0.9% 1.8% -0.7%
Gross profit growth (1Y) 2.3% 11.2% 8.5%
Gross profit CAGR (3Y) -0.4% 3.7% 4.4%
Operating income growth (1Y) -5.5% 13.5% 23.1%
Operating income CAGR (3Y) -3.7% 5.1% 30.0%
Net income growth (1Y) -16.7% 18.0% 27.5%
Net income CAGR (3Y) -33.8% 8.3% 40.9%
EPS growth (1Y) -12.3% 18.9% 28.3%
EPS CAGR (3Y) -31.2% 9.8% 41.3%
Operating cash flow growth (1Y) 6.2% 7.6% 9.6%
Operating cash flow CAGR (3Y) 86.9% -1.9% 47.5%
Free cash flow growth (1Y) 9.5% 16.5% 5.7%
Free cash flow CAGR (3Y) 64.8% -3.7% 126.5%

Profitability

14 metrics
MetricRVTYAILMN
Gross margin 55.0% 53.8% 67.9%
EBITDA margin 26.6% 25.9% 27.3%
Operating margin 12.3% 22.2% 21.2%
Pretax margin 9.0% 22.5% 23.3%
Net margin 8.2% 19.5% 19.7%
FCF margin 19.5% 17.2% 23.3%
Operating cash flow margin 21.9% 21.8% 27.1%
Return on equity 3.3% 19.9% 29.9%
Return on assets 2.0% 10.7% 13.3%
Return on invested capital 3.1% 13.1% 16.6%
Return on capital employed 3.3% 14.6% 17.2%
Asset turnover 0.2x 0.5x 0.7x
Cash conversion (OCF / net income) 2.7x 1.1x 1.4x
Stock comp / revenue 0.8% 1.8% 5.9%

Financial Health

11 metrics
MetricRVTYAILMN
Debt / assets 26.6% 28.3% 26.3%
Debt / equity 0.4x 0.5x 0.6x
Net debt / EBITDA 2.8x 1.1x 0.4x
Debt / FCF 5.6x 3.1x 1.7x
Liabilities / assets 40.0% 47.3% 53.8%
Equity / assets 60.0% 52.7% 46.2%
Interest coverage 3.7x 15.5x 9.8x
Current ratio 1.8x 2.1x 2.6x
Quick ratio 1.4x 1.4x 1.8x
Cash ratio 0.8x 0.8x 1.2x
Altman Z-score 3.26 5.72 7.10

Shareholder Returns

7 metrics
MetricRVTYAILMN
Dividend yield 0.2% 0.6% –
Net buyback yield 2.8% 0.6% 1.1%
Shareholder yield 3.0% 1.2% 1.1%
Payout ratio (earnings) 13.4% 19.9% –
Payout ratio (FCF) 5.6% 22.6% –
Dividend growth (1Y) -6.3% 2.1% –
Dividend CAGR (3Y) -6.1% 3.1% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusRVTYAILMN
Forward P/E 32.1xFY2026 26.8xFY2026 47.7xFY2026
EPS, next fiscal year $5.10FY2026 $6.54FY2026 $4.99FY2026
EPS growth, next FY +0.8%FY2026 +17.0%FY2026 +3.1%FY2026
EPS growth, the year after +11.0% +0.3% +25.7%
Revenue, next fiscal year $2.98BFY2026 $7.87BFY2026 $4.52BFY2026
Revenue growth, next FY +4.0%FY2026 +15.3%FY2026 +4.1%FY2026
Revenue growth, the year after -2.0% -5.6% +12.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersRVTYAILMN
Held by institutions 100.0% 92.6% 100.0%
Institutions holding 547 1,126 935
Change in shares held, QoQ -1.3% +3.2% +0.0%
Institutions buying 303 603 464
Institutions selling 161 350 331
Buyers to sellers 1.88 1.72 1.40

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

RVTYAILMN
RVTY 1.00 0.65 0.56
A 0.65 1.00 0.50
ILMN 0.56 0.50 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, RVTY, A and ILMN?

Agilent Technologies (A) is the largest by market capitalisation: Revvity (RVTY) $17.66B, Agilent Technologies (A) $49.95B, Illumina (ILMN) $34.25B.

Which stock is cheaper, RVTY, A and ILMN?

Agilent Technologies (A) trades on the lowest price-to-earnings ratio (Revvity (RVTY) 74.3x, Agilent Technologies (A) 34.7x, Illumina (ILMN) 38.3x). On next year's consensus earnings, Agilent Technologies (A) is cheapest (Revvity (RVTY) 32.1x, Agilent Technologies (A) 26.8x, Illumina (ILMN) 47.7x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Agilent Technologies (A) grew revenue fastest over the trailing twelve months: Revvity (RVTY) +4.1%, Agilent Technologies (A) +8.6%, Illumina (ILMN) +5.8%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Revvity (RVTY) 8.2%, Agilent Technologies (A) 19.5%, Illumina (ILMN) 19.7%). On return on invested capital, Illumina (ILMN) leads (Revvity (RVTY) 3.1%, Agilent Technologies (A) 13.1%, Illumina (ILMN) 16.6%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Revvity (RVTY) +62.1%, Agilent Technologies (A) +17.5%, Illumina (ILMN) +83.4%. Over five years, Agilent Technologies (A) compounded fastest (Revvity (RVTY) -2.7%/yr, Agilent Technologies (A) +1.7%/yr, Illumina (ILMN) -11.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Agilent Technologies (A) has the highest dividend yield: Revvity (RVTY) 0.00%, Agilent Technologies (A) 0.01%, Illumina (ILMN) 0.00%. Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Agilent Technologies (A) has been the steadiest (Revvity (RVTY) 40.1%, Agilent Technologies (A) 32.6%, Illumina (ILMN) 49.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, RVTY, A and ILMN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Agilent Technologies (A) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.